Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.39 |
| ▸ | CCR2 | P41597 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582913 | 1.00 | OPRL1 (0.44) | OPRL1OPRM1OPRK1HSD11B1CCR2 | |
| SCHEMBL30638788 | 0.86 | JAK2 (0.44) | — | |
| SCHEMBL21821643 | 0.86 | JAK2 (0.44) | — | |
| SCHEMBL21821758 | 0.86 | DRD2 (0.44) | CCR2CYP2D6 | |
| SCHEMBL29581764 | 0.86 | DRD2 (0.44) | CCR2CYP2D6 | |
| SCHEMBL22111676 | 0.84 | MEN1 (0.39) | — | |
| SCHEMBL29581966 | 0.81 | HRH3 (0.40) | — | |
| SCHEMBL21822005 | 0.81 | HRH3 (0.40) | — | |
| SCHEMBL21821928 | 0.79 | KDM4E (0.38) | — | |
| SCHEMBL29581782 | 0.79 | KDM4E (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632903-B1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-3632903-B1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3632903-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | ATG7, SQSTM1, BECN1 | OPRL1 3986/4885OPRM1 4351/4885OPRK1 4401/4885 |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | ATG7, SQSTM1, BECN1 | OPRL1 3986/4885OPRM1 4351/4885OPRK1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.